Bioxytran Secures Commercial Distribution Agreement for A-SUQAR® Dietary Supplement

summarizeSummary

Bioxytran signed a distribution agreement with Khoury Medical LTD for its A-SUQAR® dietary supplement, marking its entry into commercial revenue generation and validating its core technology platform.

check_boxKey Events

• Distribution Agreement Signed

  Bioxytran entered into a commercial Distribution Agreement with Khoury Medical LTD for its A-SUQAR® chewable dietary supplement.

• Commercialization of A-SUQAR®

  Khoury Medical will commercialize A-SUQAR®, a proprietary partially hydrolyzed guar gum (PHGG) formulation, intended to support healthy post-meal blood sugar levels.

• Strategic Shift to Commercial Revenue

  The agreement represents an important milestone for Bioxytran, transitioning it to a company with potential recurring commercial revenue and providing market validation for its technology platform.

• Preserves Pharmaceutical Focus

  The agreement is specifically for non-pharmaceutical dietary products, allowing Bioxytran to independently advance its pharmaceutical and antiviral development programs.

auto_awesomeAnalysis

Bioxytran, a micro-cap biotechnology company, has entered into a commercial distribution agreement with Khoury Medical LTD for its A-SUQAR® dietary supplement. This agreement marks a strategic shift for Bioxytran, moving it from a purely development-stage organization to one with a pathway to recurring commercial revenue. While A-SUQAR® is a nutraceutical product, it provides crucial market validation for the company's proprietary carbohydrate-based galectin platform, which also underpins its higher-value pharmaceutical and antiviral programs, including the recently successful ProLectin-M Phase 2 trial. The deal is structured to maintain a capital-efficient commercial model for Bioxytran, allowing it to focus on its core intellectual property and pharmaceutical development.